Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2- mutant refractory/relapsed AML.
| Autor: | Alhajahjeh, Abdulrahman1,2 (AUTHOR), Patel, Kishan K.3 (AUTHOR), Shallis, Rory M.4 (AUTHOR), Podoltsev, Nikolai A.4 (AUTHOR), Kewan, Tariq4 (AUTHOR), Stempel, Jessica M.4 (AUTHOR), Mendez, Lourdes4 (AUTHOR), Huntington, Scott F.4 (AUTHOR), Stahl, Maximilian5 (AUTHOR), Goshua, George4,6 (AUTHOR), Bewersdorf, Jan Philipp4 (AUTHOR), Zeidan, Amer M.4 (AUTHOR) amer.zeidan@yale.edu |
|---|---|
| Zdroj: | Leukemia & Lymphoma. Nov2024, p1-9. 9p. 3 Illustrations. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|